Karyopharm Therapeutics has a Cash Ratio of 1.18. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Karyopharm Therapeutics's Cash Ratio or its related term are showing as below:
KPTI'
s Cash Ratio Range Over the Past 10 Years
Min: 1.18 Med: 4.18 Max: 11.61
Current: 1.18
During the past 13 years, Karyopharm Therapeutics's highest Cash Ratio was 11.61. The lowest was 1.18. And the median was 4.18.
KPTI's Cash Ratio is ranked worse than 70.75% of 1470
companies
in the Biotechnology industry
Industry Median: 2.67
vs KPTI: 1.18
Karyopharm Therapeutics Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Karyopharm Therapeutics's Cash Ratio
For the Biotechnology subindustry, Karyopharm Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Karyopharm Therapeutics's Cash Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Karyopharm Therapeutics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Karyopharm Therapeutics (NAS:KPTI) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Karyopharm Therapeutics Cash Ratio Related Terms
Thank you for viewing the detailed overview of Karyopharm Therapeutics's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KPTI has been successfully added to your 